[96a5a0]: / output / allTrials / identified / NCT00104091_identified.json

Download this file

775 lines (775 with data), 34.0 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
{
"info": {
"nct_id": "NCT00104091",
"official_title": "A Multicenter Phase II Study of TP-38 in Those Patients With Glioblastoma Multiforme Who Have Recurred or Progressed After Previous Resection and Radiation Therapy and Are Scheduled for Gross Total Resection",
"inclusion_criteria": "The patients must fulfill all the following criteria:\n\n* Previous histologically-confirmed diagnosis of primary GBM (glioblastoma multiforme, glioma grade 4 at time of first diagnosis).\n* Histologically-confirmed and MRI diagnosed recurrent or progressive GBM after previous resection (surgical or biopsy) and radiation therapy.\n* Medically capable of undergoing the planned surgical gross total resection and the catheter placement.\n* Age ≥ 18.\n* Karnofsky Performance Status of ≥ 70%.\n* Life expectancy of ≥ 3 months.\n* Patients must already be taking or begin taking corticosteroids at a stable dose of 4 mg every 6 hours for at least 72 hours prior to catheter placement.\n* Patients must be capable of taking, or already taking, anticonvulsant medication.\n* Patients must have read, signed, and dated an informed consent according to ICH-GCP, the local regulatory requirement and the rules followed at each institution.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "Patients fulfilling any of the following criteria should not be enrolled in the study:\n\n* Previous myelosuppressive chemotherapy within the past 4 weeks of the start of the infusion. Patients who have received more than two chemotherapy regimens (single therapy or combination therapy) are ineligible.\n* Any form of brain radiation within 10 weeks of the start of the infusion.\n* Previous gamma knife radiosurgery, stereotactic radiosurgery, and/or internal radiotherapy, unless the recurrence/progression is histologically confirmed (fine-needle biopsy).\n* Prior intracavitary biologic response modifiers or monoclonal antibodies.\n* Uncontrolled seizures.\n* Bilateral or multifocal tumors.\n* Evidence of cerebral uncal herniation.\n* Midline brain shift on MRI scan of > 0.5 cm prior to resection; patients with subfalcine herniation may be enrolled.\n* Tumors involving the brainstem or cerebellum.\n* Diffuse subependymal or CSF disease.\n* Women who are pregnant or breast feeding. All women of child-bearing potential should be excluded unless they have a negative pregnancy test and are using adequate contraceptive measures or are surgically sterile. Post-menopausal women must be amenorrheic for at least 12 months to be considered non-childbearing.\n* Fertile males not practicing adequate contraception and whose female partners are not using adequate contraceptive protection.\n* Prior or concurrent investigational treatment within 30 days of study entry.\n* Active infection requiring treatment or having an unexplained febrile illness.\n* Systemic diseases or other conditions which may be associated with unacceptable anesthetic/operative risk and/or which would not allow safe completion of this study protocol.\n* Prior or concurrent malignancy (curatively treated carcinoma-in-situ or basal cell carcinoma or patients who have been disease free for at least 5 years are eligible).",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Previous histologically-confirmed diagnosis of primary GBM (glioblastoma multiforme, glioma grade 4 at time of first diagnosis).",
"criterions": [
{
"exact_snippets": "Previous histologically-confirmed diagnosis of primary GBM (glioblastoma multiforme, glioma grade 4 at time of first diagnosis)",
"criterion": "primary GBM diagnosis",
"requirements": [
{
"requirement_type": "confirmation method",
"expected_value": "histologically-confirmed"
},
{
"requirement_type": "grade",
"expected_value": "glioma grade 4"
}
]
}
]
},
{
"line": "* Histologically-confirmed and MRI diagnosed recurrent or progressive GBM after previous resection (surgical or biopsy) and radiation therapy.",
"criterions": [
{
"exact_snippets": "Histologically-confirmed",
"criterion": "histological confirmation",
"requirements": [
{
"requirement_type": "confirmation",
"expected_value": true
}
]
},
{
"exact_snippets": "MRI diagnosed",
"criterion": "MRI diagnosis",
"requirements": [
{
"requirement_type": "diagnosis",
"expected_value": true
}
]
},
{
"exact_snippets": "recurrent or progressive GBM",
"criterion": "GBM status",
"requirements": [
{
"requirement_type": "status",
"expected_value": [
"recurrent",
"progressive"
]
}
]
},
{
"exact_snippets": "after previous resection (surgical or biopsy)",
"criterion": "previous resection",
"requirements": [
{
"requirement_type": "type",
"expected_value": [
"surgical",
"biopsy"
]
}
]
},
{
"exact_snippets": "after ... radiation therapy",
"criterion": "previous radiation therapy",
"requirements": [
{
"requirement_type": "completion",
"expected_value": true
}
]
}
]
},
{
"line": "* Medically capable of undergoing the planned surgical gross total resection and the catheter placement.",
"criterions": [
{
"exact_snippets": "Medically capable of undergoing the planned surgical gross total resection",
"criterion": "medical capability for surgical gross total resection",
"requirements": [
{
"requirement_type": "capability",
"expected_value": true
}
]
},
{
"exact_snippets": "Medically capable of undergoing ... the catheter placement",
"criterion": "medical capability for catheter placement",
"requirements": [
{
"requirement_type": "capability",
"expected_value": true
}
]
}
]
},
{
"line": "* Age ≥ 18.",
"criterions": [
{
"exact_snippets": "Age ≥ 18",
"criterion": "age",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "* Karnofsky Performance Status of ≥ 70%.",
"criterions": [
{
"exact_snippets": "Karnofsky Performance Status of ≥ 70%",
"criterion": "Karnofsky Performance Status",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": ">=",
"value": 70,
"unit": "%"
}
}
]
}
]
},
{
"line": "* Life expectancy of ≥ 3 months.",
"criterions": [
{
"exact_snippets": "Life expectancy of ≥ 3 months.",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "months"
}
}
]
}
]
},
{
"line": "* Patients must already be taking or begin taking corticosteroids at a stable dose of 4 mg every 6 hours for at least 72 hours prior to catheter placement.",
"criterions": [
{
"exact_snippets": "Patients must already be taking or begin taking corticosteroids",
"criterion": "corticosteroid usage",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "at a stable dose of 4 mg every 6 hours",
"criterion": "corticosteroid dosage",
"requirements": [
{
"requirement_type": "dosage",
"expected_value": {
"operator": "=",
"value": 4,
"unit": "mg every 6 hours"
}
}
]
},
{
"exact_snippets": "for at least 72 hours prior to catheter placement",
"criterion": "corticosteroid duration",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 72,
"unit": "hours"
}
}
]
}
]
},
{
"line": "* Patients must be capable of taking, or already taking, anticonvulsant medication.",
"criterions": [
{
"exact_snippets": "capable of taking, or already taking, anticonvulsant medication",
"criterion": "anticonvulsant medication",
"requirements": [
{
"requirement_type": "capability",
"expected_value": true
},
{
"requirement_type": "current use",
"expected_value": true
}
]
}
]
},
{
"line": "* Patients must have read, signed, and dated an informed consent according to ICH-GCP, the local regulatory requirement and the rules followed at each institution.",
"criterions": [
{
"exact_snippets": "Patients must have read, signed, and dated an informed consent",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "completion",
"expected_value": true
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Previous myelosuppressive chemotherapy within the past 4 weeks of the start of the infusion. Patients who have received more than two chemotherapy regimens (single therapy or combination therapy) are ineligible.",
"criterions": [
{
"exact_snippets": "Previous myelosuppressive chemotherapy within the past 4 weeks of the start of the infusion.",
"criterion": "previous myelosuppressive chemotherapy",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"operator": "<=",
"value": 4,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "Patients who have received more than two chemotherapy regimens (single therapy or combination therapy) are ineligible.",
"criterion": "number of chemotherapy regimens received",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "regimens"
}
}
]
}
]
},
{
"line": "* Any form of brain radiation within 10 weeks of the start of the infusion.",
"criterions": [
{
"exact_snippets": "Any form of brain radiation within 10 weeks of the start of the infusion.",
"criterion": "brain radiation",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"operator": "<=",
"value": 10,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* Previous gamma knife radiosurgery, stereotactic radiosurgery, and/or internal radiotherapy, unless the recurrence/progression is histologically confirmed (fine-needle biopsy).",
"criterions": [
{
"exact_snippets": "Previous gamma knife radiosurgery",
"criterion": "previous gamma knife radiosurgery",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "stereotactic radiosurgery",
"criterion": "previous stereotactic radiosurgery",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "internal radiotherapy",
"criterion": "previous internal radiotherapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "recurrence/progression is histologically confirmed (fine-needle biopsy)",
"criterion": "histological confirmation of recurrence/progression",
"requirements": [
{
"requirement_type": "confirmation",
"expected_value": true
}
]
}
]
},
{
"line": "* Prior intracavitary biologic response modifiers or monoclonal antibodies.",
"criterions": [
{
"exact_snippets": "Prior intracavitary biologic response modifiers",
"criterion": "intracavitary biologic response modifiers",
"requirements": [
{
"requirement_type": "prior use",
"expected_value": true
}
]
},
{
"exact_snippets": "Prior ... monoclonal antibodies",
"criterion": "monoclonal antibodies",
"requirements": [
{
"requirement_type": "prior use",
"expected_value": true
}
]
}
]
},
{
"line": "* Uncontrolled seizures.",
"criterions": [
{
"exact_snippets": "Uncontrolled seizures",
"criterion": "seizures",
"requirements": [
{
"requirement_type": "control",
"expected_value": false
}
]
}
]
},
{
"line": "* Bilateral or multifocal tumors.",
"criterions": [
{
"exact_snippets": "Bilateral or multifocal tumors",
"criterion": "tumors",
"requirements": [
{
"requirement_type": "location",
"expected_value": [
"bilateral",
"multifocal"
]
}
]
}
]
},
{
"line": "* Evidence of cerebral uncal herniation.",
"criterions": [
{
"exact_snippets": "Evidence of cerebral uncal herniation",
"criterion": "cerebral uncal herniation",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Midline brain shift on MRI scan of > 0.5 cm prior to resection; patients with subfalcine herniation may be enrolled.",
"criterions": [
{
"exact_snippets": "Midline brain shift on MRI scan of > 0.5 cm",
"criterion": "midline brain shift",
"requirements": [
{
"requirement_type": "severity",
"expected_value": {
"operator": ">",
"value": 0.5,
"unit": "cm"
}
}
]
},
{
"exact_snippets": "subfalcine herniation",
"criterion": "subfalcine herniation",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Tumors involving the brainstem or cerebellum.",
"criterions": [
{
"exact_snippets": "Tumors involving the brainstem",
"criterion": "tumors involving the brainstem",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Tumors involving the ... cerebellum",
"criterion": "tumors involving the cerebellum",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Diffuse subependymal or CSF disease.",
"criterions": [
{
"exact_snippets": "Diffuse subependymal",
"criterion": "subependymal disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "CSF disease",
"criterion": "CSF disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Women who are pregnant or breast feeding. All women of child-bearing potential should be excluded unless they have a negative pregnancy test and are using adequate contraceptive measures or are surgically sterile. Post-menopausal women must be amenorrheic for at least 12 months to be considered non-childbearing.",
"criterions": [
{
"exact_snippets": "Women who are pregnant",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "breast feeding",
"criterion": "breastfeeding",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "All women of child-bearing potential ... negative pregnancy test",
"criterion": "pregnancy test",
"requirements": [
{
"requirement_type": "result",
"expected_value": "negative"
}
]
},
{
"exact_snippets": "All women of child-bearing potential ... using adequate contraceptive measures",
"criterion": "contraceptive measures",
"requirements": [
{
"requirement_type": "usage",
"expected_value": true
}
]
},
{
"exact_snippets": "All women of child-bearing potential ... surgically sterile",
"criterion": "surgical sterility",
"requirements": [
{
"requirement_type": "status",
"expected_value": true
}
]
},
{
"exact_snippets": "Post-menopausal women must be amenorrheic for at least 12 months",
"criterion": "amenorrhea duration",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 12,
"unit": "months"
}
}
]
}
]
},
{
"line": "* Fertile males not practicing adequate contraception and whose female partners are not using adequate contraceptive protection.",
"criterions": [
{
"exact_snippets": "Fertile males",
"criterion": "fertility",
"requirements": [
{
"requirement_type": "fertility",
"expected_value": "fertile"
}
]
},
{
"exact_snippets": "not practicing adequate contraception",
"criterion": "contraception practice",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": false
}
]
},
{
"exact_snippets": "female partners are not using adequate contraceptive protection",
"criterion": "female partner contraception",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": false
}
]
}
]
},
{
"line": "* Prior or concurrent investigational treatment within 30 days of study entry.",
"criterions": [
{
"exact_snippets": "Prior or concurrent investigational treatment",
"criterion": "investigational treatment",
"requirements": [
{
"requirement_type": "timing",
"expected_value": "prior or concurrent"
},
{
"requirement_type": "time frame",
"expected_value": {
"operator": "<=",
"value": 30,
"unit": "days"
}
}
]
}
]
},
{
"line": "* Active infection requiring treatment or having an unexplained febrile illness.",
"criterions": [
{
"exact_snippets": "Active infection requiring treatment",
"criterion": "active infection",
"requirements": [
{
"requirement_type": "treatment requirement",
"expected_value": true
}
]
},
{
"exact_snippets": "unexplained febrile illness",
"criterion": "febrile illness",
"requirements": [
{
"requirement_type": "explanation",
"expected_value": false
}
]
}
]
},
{
"line": "* Systemic diseases or other conditions which may be associated with unacceptable anesthetic/operative risk and/or which would not allow safe completion of this study protocol.",
"criterions": [
{
"exact_snippets": "Systemic diseases or other conditions which may be associated with unacceptable anesthetic/operative risk",
"criterion": "systemic diseases or other conditions",
"requirements": [
{
"requirement_type": "anesthetic/operative risk",
"expected_value": "unacceptable"
}
]
},
{
"exact_snippets": "Systemic diseases or other conditions ... which would not allow safe completion of this study protocol",
"criterion": "systemic diseases or other conditions",
"requirements": [
{
"requirement_type": "completion of study protocol",
"expected_value": "not safe"
}
]
}
]
},
{
"line": "* Prior or concurrent malignancy (curatively treated carcinoma-in-situ or basal cell carcinoma or patients who have been disease free for at least 5 years are eligible).",
"criterions": [
{
"exact_snippets": "Prior or concurrent malignancy",
"criterion": "malignancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "curatively treated carcinoma-in-situ",
"criterion": "carcinoma-in-situ",
"requirements": [
{
"requirement_type": "treatment status",
"expected_value": "curatively treated"
}
]
},
{
"exact_snippets": "curatively treated ... basal cell carcinoma",
"criterion": "basal cell carcinoma",
"requirements": [
{
"requirement_type": "treatment status",
"expected_value": "curatively treated"
}
]
},
{
"exact_snippets": "disease free for at least 5 years",
"criterion": "disease-free status",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 5,
"unit": "years"
}
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [
{
"line": "The patients must fulfill all the following criteria:",
"criterions": []
}
],
"failed_exclusion": [
{
"line": "Patients fulfilling any of the following criteria should not be enrolled in the study:",
"criterions": []
}
],
"failed_miscellaneous": []
}